C2N’s New Blood Test Combining p-tau217 Ratio with A?42/40 Ratio Points to Accuracy Levels Comparable to Existing Standards of Care for Amyloid Diagnosis in the Evaluation of Patients with Cognitive Impairment

SAN DIEGO–(BUSINESS WIRE)– #AAIC2022–Data released from C2N Diagnostics, presented today at the Alzheimer’s Association International Conference, demonstrated that a blood test combining the A?42/40 ratio, a component of C2N’s commercially available PrecivityADTM blood test, with a unique p-tau217 ratio leads to testing performance that points to accuracy comparable to more complex amyloid PET imaging and invasive cerebrospinal fluid tests in identifying Alzheimer’s brain pathology. The study, based on
Click here to view original post